Mavacamten sales could be near $1 billion if OKed for HCM, says analyst
US pharma major Bristol Myers Squibb’s (NYSE: BMY) mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) market, achieving around $958 million in sales by 2025, according to data and analytics company GlobalData.
The firm’s pharmaceutical analyst Sarah Bundra noted that “mavacamten will be the first drug to specifically target obstructive HCM, which is a common form of cardiomyopathy. It has a unique mechanism of action (MoA) - being a myosin inhibitor—that more closely targets the pathophysiology of the disease.”
Existing cardiomyopathy therapies are generic and used for a wide range of cardiovascular diseases. Mavacamten can be used in conjunction with marketed therapies, such as beta blockers. As such, the drug will not displace any current therapy options, but will address a key cardiomyopathy demographic that has not previously been the target of clinical trial development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze